Small-molecule MDM2-p53 inhibitors: recent advances.

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• The p53 tumor suppressor protein is crucial for preventing cancer.
• MDM2 inhibits p53 activity, and its overexpression is common in p53 wild-type tumors.
• Targeting the p53-MDM2 interaction offers a therapeutic strategy for these cancers.

Purpose of the Study:

• To review recent advancements in small-molecule inhibitors of the p53-MDM2 interaction.
• To highlight compounds that have reached advanced optimization and clinical trials.
• To analyze structure-activity relationships and common structural features of these inhibitors.

Main Methods:

• Literature review of recent disclosures on p53-MDM2 inhibitors.
• Analysis of structure-activity relationships (SAR) for various inhibitor classes.
• Examination of X-ray crystallographic data to understand inhibitor binding.

Main Results:

• Several chemical series of potent and selective p53-MDM2 inhibitors have been identified.
• Compounds in advanced optimization and clinical development are discussed.
• Key structural features and SAR trends across different inhibitor classes are elucidated.

Conclusions:

• Small-molecule inhibitors targeting the p53-MDM2 interaction are promising for p53 wild-type tumors.
• Continued optimization and clinical investigation are yielding potential cancer therapeutics.
• Understanding SAR and structural features guides the design of next-generation inhibitors.